GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...

GSK has agreed to pay up to $2.2 billion to resolve ... The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S., most of which had been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

Sept 11 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial ...

BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK delivered promising response rates in patients with a type of lung cancer, propelling the ...

iTeos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...